Interleukin-33 (IL-33) functions both as a secreted cytokine and as a nuclear factor, with pleiotropic roles in cancer and immunity. Here, we explored its role in hepatocellular carcinoma (HCC) and identified that a posttranslational modification altered its nuclear activity and promoted immune escape for HCC. IL-33 abundance was overall decreased but more frequently localized to the nucleus in patient HCC tissues than in normal liver tissues. In human and mouse HCC cells in culture and in vivo, IL-33 overexpression inhibited proliferation and repressed the abundance of programmed death ligand 1 (PD-L1) at the transcriptional level by promoting the ubiquitin-dependent degradation of interferon regulatory factor 1 (IRF1). However, this interaction was disrupted by SUMOylation of IL-33 at Lys 54 mediated by the E3 ligase RanBP2. IL-33 SUMOylation correlated with its nuclear localization in HCC cells and tumors. An increase in SUMOylated IL-33 in HCC cells in cocultures and in vivo stabilized IRF1 and increased PD-L1 abundance and chemokine IL-8 secretion, which prevented the activation of cytotoxic T cells and promoted the M2 polarization of macrophages, respectively. Mutating the SUMOylation site in IL-33 reversed these effects and suppressed tumor growth. These findings indicate that SUMOylation of nuclear IL-33 in HCC cells impairs antitumor immunity.
Nonerythrocytic alphaII‐spectrin (SPTAN1) is crucial for neuronal functions, yet its role in oncogenic processes remains inadequately characterized. This study investigates the lactylation (kla) modification of SPTAN1 (SPTAN1‐kla) and its mechanistic contributions to hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC). Results indicate that SPTAN1 undergoes lactylation at lysine residues K1952 and K1957 specifically in HBV‐positive HCC tissues. Alanyl‐tRNA synthetase 1 (AARS1) mediates SPTAN1‐kla formation, while histone deacetylase 1 (HDAC1) acts as a delactylase. HBV infection enhances lactate production by inducing the expression of HK2, promoting SPTAN1‐kla formation, and disrupting the liquid‐liquid phase separation (LLPS) of cytoplasmic SPTAN1, thereby facilitating its nuclear translocation. Within the nucleus, SPTAN1‐kla interacts with core‐binding factor β (CBFB) to activate NOTCH1/HES1 signaling, thereby promoting HCC cell proliferation. Furthermore, SPTAN1‐kla activates the COX2/mPGES1 pathway through NOTCH1/HES1 signaling, thereby enhancing the biosynthesis of prostaglandin E2 (PGE2) and increasing the infiltration of exhausted CD8⁺ T cells. Therapeutic targeting of SPTAN1‐kla using specific inhibitory peptides significantly attenuates HCC tumor growth in preclinical models. Our research identifies SPTAN1‐kla as a novel oncogenic driver in HBV‐related HCC, functioning via metabolic reprogramming and immune modulation. These findings position SPTAN1‐kla as a promising therapeutic target for developing precision interventions against HBV‐related HCC.
Variable splicing (AS) plays important roles in tumor progression. However, the role of the AS factor RBM17 in the progression of hepatocellular carcinoma (HCC) has not yet been elucidated. We used label-free proteomics, single-cell sequencing (scRNA-seq), high throughput sequencing, flow cytometry (FCM), liquid Chromatography-tandem mass spectrometry (LC‒MS/MS), multiparametric immunofluorescence (mIF) and chromatin immunoprecipitation (Chip), to explore the relationship between RBM17 regulation of HCC cell lipid metabolism and the immune microenvironment. Our findings revealed that RBM17 is significantly overexpressed in HCC tissue and is positively correlated with poor prognosis. We found a positive correlation between RBM17 expression and M2 macrophage infiltration. Mechanistically, RBM17 promotes M2 macrophage infiltration by inducing taurocholic acid (T-CA) production, which is achieved through enhancing exon exclusion of CSAD precursor mRNA. Additionally, RBM17 modulates fatty acid metabolism and CD8+ T cell infiltration by regulating exon skipping in HACD3 precursor mRNA. Furthermore, RUNX1 activates RBM17 expression and regulates downstream CSAD/T-CA and HACD3/FFA signaling. Importantly, targeting RBM17 can prevent HCC progression, suggesting its potential as a therapeutic target for HCC. Our findings provide new insights into the mechanisms underlying immune cell infiltration and metabolism in HCC and identify RBM17 as a promising therapeutic target.
Macrophage antigen presentation is crucial for adaptive immunity and maintaining immune balance, including anti-infection, anti-tumor, and inflammation regulation. However, its role in tumor immunomodulation is less understood compared to macrophage polarization. This study explored how Rnaseh2c+ macrophages influence hepatocellular carcinoma (HCC) progression using in vitro cell models and mouse tumor models. Single-cell RNA sequencing, immunoblotting, immunofluorescence, immunoprecipitation, and flow cytometry analysis were employed to examine RNASEH2C’s impact on macrophage antigen presentation. Our results indicated that Rnaseh2c+ macrophages, which were non-polarized, promoted HCC growth by inhibiting antigen presentation. RNASEH2C facilitated lysosomal degradation of RAI14 by enhancing TRAF3IP1 expression and suppressing the mTOR pathway, with HSC70 and CMTM6 playing opposing roles in RAI14 degradation. RAI14, a skeleton protein, facilitated the macropinocytosis of MHC II molecules and tumor-associated antigen, thus activating Th1 cells in HCC. In conclusion, our study revealed how RNASEH2C mediated RAI14’s lysosomal degradation, offering potential targets and strategies for HCC immunotherapy.
15 April 2026 in Journal for ImmunoTherapy of Cancer
Background: Tumor-associated macrophages are pivotal drivers of hepatocellular carcinoma (HCC) progression. However, the functional contributions of proliferating macrophages (Prolif Ms) within the tumor microenvironment (TME) remain poorly defined. Methods: Here, we integrated single-cell RNA sequencing, Cleavage Under Targets and Tagmentation (CUT&Tag), bulk RNA sequencing, multiparametric immunofluorescence, flow cytometry, and molecular dynamics simulation to dissect the phenotype, functional landscape, and targeting strategy of Prolif Ms in HCC. Results: We identified a novel Prolif Ms subset characterized by high expression of proliferation markers (Cdk1, Mki67), distinct from classical M1/M2 macrophages. Mechanistically, ribonuclease H2 subunit C (Rnaseh2c) acts as a non-enzymatic regulator, binding directly to the cyclin-dependent kinase promoter to drive macrophage proliferation while suppressing endocytic and antigen-presenting capabilities. Rnaseh2c further promotes CD8 + exhausted T cell (CD8 + T ex ) infiltration via the C-C motif chemokine ligand 2/C-C motif chemokine receptor type 2 (CCL2/CCR2) axis, fostering an immunosuppressive TME. Notably, Rnaseh2c exhibits cancer-promoting effects in both macrophages and hepatocytes. We developed a specific inhibitor “Rnaseh2c-In1”, which inhibits HCC growth by reducing CCL2 secretion and CD8 + T ex infiltration, demonstrating favorable pharmacokinetics and low toxicity. Conclusions: This study elucidates a non-enzymatic Rnaseh2c-driven mechanism regulating Prolif Ms, providing a novel therapeutic target and candidate compound for HCC treatment.